Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“We conclude that NAC has antagonistic effects on Bleomycin‐induced apoptosis in NT2 cells and causes resistance to apoptosis which is not a desired effect in eliminating cancer cells.”
Journal of cellular biochemistry • 2013 | View Paper
“Co-incubation with NAC significantly decreased lipid hydroperoxide, 8-isoprostane, protein carbonyl content and TBARS levels increased by bleomycin and H(2)O(2).”
“It can be concluded that NAC diminishes oxidative stress in human testicular cancer cells induced by bleomycin and H(2)O(2).”
“Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.”
Journal of Physiology and Biochemistry • 2012 | View Paper
“As expected on this basis, the diamine WR‐1065 is a more effective potentiator of BLM than is the monoamine CSM, whereas cysteine and N‐acetylcysteine (NAC), which lack a net positive charge, potentiate BLM only weakly.”
Pulmonary pharmacology & therapeutics • 2008 | View Paper
“ Bleomycin administration resulted in prominent lung fibrosis as measured by lung hydroxyproline content and lung histology which is almost completely prevented by erdosteine and NAC.”
Pulmonary pharmacology & therapeutics • 2005 | View Paper
“At 15 days postbleomycin, N‐acetylcysteine decreased collagen deposition in bleomycin‐exposed rats (hydroxyproline content: 6351±669 and 4626±288 μg per lung in drug vehicle‐ and N‐acetylcysteine‐treated rats, respectively; P<0.05).”
“These results indicate that N‐acetylcysteine reduces the primary inflammatory events, thus preventing cellular damage and the subsequent development of pulmonary fibrosis in the bleomycin rat model.”
British journal of pharmacology • 2003 | View Paper
“Nrf-1 and -2 activation by bleomycin is inhibited by the ROS quenching agent N-acetylcysteine (NAC), but not by U-0126, a MEK1/2 inhibitor that blocks bleomycin-induced MAPK activation.”